Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer

Koren, Ana (avtor), Rijavec, Matija (avtor), Krumpestar, Tomaž (avtor), Kern, Izidor (avtor), Sadikov, Aleksander (avtor), Čufer, Tanja (avtor), Korošec, Peter (avtor)

Background: Hypoxia correlates with poor prognosis in several cancer types, including lung cancer. Prolyl hydroxylase domain proteins (PHDs) play a role in cell oxygen sensing, negatively regulating the hypoxia-inducible factor (HIF) pathway. Our study aim was to evaluate PHD1, PHD2 and PHD3 mRNA expression levels in primary tumours and normal lungs of non-small-cell lung cancer (NSCLC) patients and to correlate it with selected regulators of HIF signalling, with clinicopathological characteristics and overall survival (OS). Methods: Tumour tissue samples were obtained from 60 patients with surgically resected NSCLC who were treated with radical surgery. In 22 out of 60 cases, matching morphologically normal lung tissue was obtained. PHD1, PHD2 and PHD3 mRNA expressions were measured using RT-qPCR. Results: The PHD1 and PHD2 mRNA levels in primary tumours were significantly decreased compared to those in normal lungs (both p < 0.0001). PHD1 and PHD2 expression in tumours was positively correlated (r$_s$ = 0.82; p < 0.0001) and correlated well with HIF pathway downstream genes HIF1A, PKM2 and PDK1. Decreased PHD1 and PHD2 were associated with larger tumour size, higher tumour stage (PHD1 only) and squamous cell carcinoma. Patients with low PHD1 and patients with low PHD2 expression had shorter OS than patients with high PHD1 (p = 0.02) and PHD2 expression (p = 0.01). PHD1 showed borderline independent prognostic values in multivariate analysis (p = 0.06). In contrast, we found no associations between PHD3 expression and any of the observed parameters. Conclusions: Our results show that reduced expression of PHD1 and PHD2 is associated with the development and progression of NSCLC. PHD1 could be further assessed as a prognostic marker in NSCLC.

• Jezik: Angleški jezik
• Ključne besede: non-small-cell lung cancer, mRNA expression, prolyl hydroxylase domain proteins, carcinoma, prognosis
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FRI - Fakulteta za računalništvo in informatiko; MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: 14 str.
• Številčenje: Vol. 13, iss. 10, art. 2309
• PID: 20.500.12556/RUL-135654
• UDK: 616-006
• ISSN pri članku: 2072-6694
• DOI: 10.3390/cancers13102309
• COBISS.SI-ID: 63269891
• Datum objave v RUL: 23.03.2022

KOREN, Ana, RIJAVEC, Matija, KRUMPESTAR, Tomaž, KERN, Izidor, SADIKOV, Aleksander, ČUFER, Tanja in KOROŠEC, Peter, 2021, Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer. Cancers [na spletu]. 2021. Vol. 13, no. 10,  2309. [Dostopano 26 marec 2025]. DOI 10.3390/cancers13102309. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=135654

Gradivo je del revije

• Naslov: Cancers
• Skrajšan naslov: Cancers
• Založnik: MDPI
• ISSN: 2072-6694
• COBISS.SI-ID: 517914137

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 12.05.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: izražanje mRNA, beljakovine s prolil hidroksilazno domeno, nedrobnocelični karcinom pljuč, prognoza

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: J3-7372
• Naslov: Molekularni označevalci raka pljuč in njim prilagojeno zdravljenje

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P3-0360
• Naslov: Celostna obravnava alergijskih bolezni in astme v Sloveniji: od epidemiologije do genetike